

Randomized Controlled Trial > J Clin Psychiatry. 2008 Mar;69(3):441-51.
doi: 10.4088/jcp.v69n0315.

FULL TEXT LINKS



Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial

David H Avery ¹, Keith E Isenberg, Shirlene M Sampson, Philip G Janicak, Sarah H Lisanby, Daniel F Maixner, Colleen Loo, Michael E Thase, Mark A Demitrack, Mark S George

Affiliations + expand

PMID: 18294022 DOI: [10.4088/jcp.v69n0315](https://doi.org/10.4088/jcp.v69n0315)

Abstract

Background: This report describes the results of an open-label extension study of active transcranial magnetic stimulation (TMS) in medication-resistant patients with major depressive disorder who did not benefit from an initial course of therapy in a previously reported 6-week, randomized controlled study of active versus sham TMS.

Method: Patients with DSM-IV-defined major depressive disorder were actively enrolled in the study from February 2004 through September 2005 and treated with left prefrontal TMS administered 5 times per week at 10 pulses per second, at 120% of motor threshold, for a total of 3000 pulses/session. The primary outcome was the baseline to endpoint change score on the Montgomery-Asberg Depression Rating Scale (MADRS).

Results: In those patients who received sham in the preceding randomized controlled trial (N = 85), the mean reduction in MADRS scores after 6 weeks of open-label active TMS was -17.0 (95% CI = -14.0 to -19.9). Further, at 6 weeks, 36 (42.4%) of these patients achieved response on the MADRS, and 17 patients (20.0%) remitted (MADRS score < 10). For those patients who received and did not respond to active TMS in the preceding randomized controlled trial (N = 73), the mean reduction in MADRS scores was -12.5 (95% CI = -9.7 to -15.4), and response and remission rates were 26.0% and 11.0%, respectively, after 6 weeks of additional open-label TMS treatment.

Conclusions: This open-label study provides further evidence that TMS is a safe and effective treatment of major depressive disorder. Furthermore, continued active TMS provided additional benefit to some patients who failed to respond to 4 weeks of treatment, suggesting that longer courses of treatment may confer additional therapeutic benefit.

Trial registration: clinicaltrials.gov Identifier: [NCT00104611](https://clinicaltrials.gov/ct2/show/NCT00104611).

[PubMed Disclaimer](#)

Similar articles

[Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.](#)

O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA.

Biol Psychiatry. 2007 Dec 1;62(11):1208-16. doi: 10.1016/j.biopsych.2007.01.018. Epub 2007 Jun 14.

PMID: 17573044 Clinical Trial.

[Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial.](#)

Lisanby SH, Husain MM, Rosenquist PB, Maixner D, Gutierrez R, Krystal A, Gilmer W, Marangell LB, Aaronson S, Daskalakis ZJ, Canterbury R, Richelson E, Sackeim HA, George MS.

Neuropsychopharmacology. 2009 Jan;34(2):522-34. doi: 10.1038/npp.2008.118. Epub 2008 Aug 13.

PMID: 18704101 Clinical Trial.

[Novel Augmentation Strategies in Major Depression.](#)

Martiny K.

Dan Med J. 2017 Apr;64(4):B5338.

PMID: 28385173 Review.

[Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes.](#)

Solvason HB, Husain M, Fitzgerald PB, Rosenquist P, McCall WV, Kimball J, Gilmer W, Demitrack MA, Lisanby SH.

Brain Stimul. 2014 Mar-Apr;7(2):219-25. doi: 10.1016/j.brs.2013.10.008. Epub 2013 Nov 4.

PMID: 24332384 Clinical Trial.

[The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.](#)

Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wierck TS.

Brain Stimul. 2016 May-Jun;9(3):336-346. doi: 10.1016/j.brs.2016.03.010. Epub 2016 Mar 16.

PMID: 27090022 [Free PMC article.](#) Review.

[See all similar articles](#)

Cited by

[Interventional Mental Health: A Transdisciplinary Approach to Novel Psychiatric Care Delivery.](#)

Kuo J, Block T, Nicklay M, Lau B, Green M.

Cureus. 2023 Aug 15;15(8):e43533. doi: 10.7759/cureus.43533. eCollection 2023 Aug.

PMID: 37719598 [Free PMC article.](#) Review.

[Neuronavigated repetitive transcranial magnetic stimulation improves depression, anxiety and motor symptoms in Parkinson's disease.](#)

Jiang S, Zhan C, He P, Feng S, Gao Y, Zhao J, Wang L, Zhang Y, Nie K, Qiu Y, Wang L.

Heliyon. 2023 Jul 17;9(8):e18364. doi: 10.1016/j.heliyon.2023.e18364. eCollection 2023 Aug.

PMID: 37533995 [Free PMC article.](#)

[Add-On Intermittent Theta Burst Stimulation Improves the Efficacy of First-Episode and Recurrent Major Depressive Disorder: Real-World Clinical Practice.](#)

Li G, Lei L, Yang C, Liu Z, Zhang KR.

Neuropsychiatr Dis Treat. 2023 Jan 13;19:109-116. doi: 10.2147/NDT.S388774. eCollection 2023.

PMID: 36660319 [Free PMC article.](#)

[Adjunctive accelerated repetitive transcranial magnetic stimulation for older patients with depression: A systematic review.](#)

Zheng W, Zhang XY, Xu R, Huang X, Zheng YJ, Huang XB, Li ZZ, Chen HD.

Front Aging Neurosci. 2022 Oct 24;14:1036676. doi: 10.3389/fnagi.2022.1036676. eCollection 2022.

PMID: 36353689 [Free PMC article.](#)

[Bilateral repetitive transcranial magnetic stimulation ameliorated sleep disorder and hypothalamic-pituitary-adrenal axis dysfunction in subjects with major depression.](#)

Chen X, Jiang F, Yang Q, Zhang P, Zhu H, Liu C, Zhang T, Li W, Xu J, Shen H.

Front Psychiatry. 2022 Aug 25;13:951595. doi: 10.3389/fpsyt.2022.951595. eCollection 2022.

PMID: 36090377 [Free PMC article.](#)

[See all "Cited by" articles](#)

Publication types

> Randomized Controlled Trial

> Research Support, Non-U.S. Gov't

MeSH terms

> Adolescent

> Adult

> Aged

> Cognition Disorders / diagnosis

> Cognition Disorders / epidemiology

> Depressive Disorder, Major / therapy*

> Diagnostic and Statistical Manual of Mental Disorders

> Female

> Humans

> Male

> Middle Aged

> Neuropsychological Tests

> Remission Induction

> Severity of Illness Index

> Surveys and Questionnaires

> Transcranial Magnetic Stimulation / methods*

> Treatment Outcome

Associated data

> ClinicalTrials.gov/NCT00104611

Related information

Cited in Books

MedGen

PubChem Compound

PubChem Substance Links

LinkOut - more resources

Full Text Sources

Physicians Postgraduate Press, Inc.

Medical

ClinicalTrials.gov

Genetic Alliance

